论文部分内容阅读
Objective: To explore the clinical significance of the examination of serum CA125 level of patients with metastatic bladder carcinoma. Methods: Electrochemiluminescence technique was used to examine the serum CA125 concentration of 58 cases with metastatic bladder cancer. 30 cases of superficial bladder cancer and 8 cases of other urological diseases were collected as the control group. Results: Serum CA125 level in 39 (67.2%) out of 58 cases ranged from 36.7 U/mL to 1485.6 U/mL (mean 498.3 U/mL), being higher than normal (< 35 U/mL). Serum CA125 level of metastatic bladder cancer patients was 324.5 U/mL, significantly higher than that in control group (P < 0.001). Serum CA125 level of 10 patients after transure- thral resection operation was significantly lower than that before operation (P < 0.05). Serum CA125 level of 16 patients who refused further treatment significantly increased from 450.4 U/mL, to 505.8 U/mL (P = 0.041) 3 months after discharge from the hospital. Serum CA125 level of 17 patients significantly decreased from 475.8 U/L to 237.9 U/mL (P < 0.001) after bilateral iliac-arterial embolism treatment. Conclusion: CA125 may be a valuable marker for the judgment of advanced metastatic bladder cancer.
Objective: To explore the clinical significance of the examination of serum CA125 level of patients with metastatic bladder carcinoma. Methods: Electrochemiluminescence technique was used to examine the serum CA125 concentration of 58 cases with metastatic bladder cancer. 30 cases of superficial bladder cancer and 8 cases of other urological diseases were collected as the control group. Results: Serum CA125 level in 39 (67.2%) out of 58 cases ranged from 36.7 U / mL to 1485.6 U / mL (mean 498.3 U / mL) <35 U / mL) Serum CA125 level of metastatic bladder cancer patients was 324.5 U / mL, significantly higher than that in control group (P <0.001). Serum CA125 level of 10 patients after transurethral resection operation was significantly lower than Serum CA125 level of 16 patients who even treated significantly increased from 450.4 U / mL to 505.8 U / mL (P = 0.041) for 3 months after discharge from the hospital. vel of 17 patients significantly decreased from 475.8 U / L to 237.9 U / mL (P <0.001) after bilateral iliac-arterial embolism treatment. Conclusion: CA125 may be a great marker for the judgment of advanced metastatic bladder cancer.